Publications
93
Citations
3,827
Est. group size
~46
Recurring co-author estimate
Active years
56
Publishing since 1971
John P. Evans conducts research spanning virology, cell biology, and drug discovery, with substantial work on how SARS-CoV-2 variants enter cells and evade antibody responses generated by vaccination or prior infection. The lab also develops chemical biology tools and small-molecule approaches, including compounds that degrade or inhibit specific proteins (such as FAK-degrading PROTACs and SARM1 inhibitors relevant to nerve degeneration), and methods to measure how drug-like compounds bind targets inside living cells. This suggests a research group working at the intersection of infectious disease and pharmacology/drug discovery.
Publication output rose sharply from 2020 to a peak in 2021-2022, likely reflecting COVID-19-related research, before declining in more recent years (2023-2025).
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- Therapeutic safety implications of SARM1 active site inhibitors: subinhibitory concentrations cause neurodegeneration
npj Drug Discovery. · 2025
- SARM1 orthosteric base exchange inhibitors cause subinhibitory SARM1 activation
bioRxiv (Cold Spring Harbor Laboratory) · 2024
- Determinants and Mechanisms of the Low Fusogenicity and High Dependence on Endosomal Entry of Omicron Subvariants
mBio · 2023
- Challenges and Prospects in Developing Future SARS-CoV-2 Vaccines: Overcoming Original Antigenic Sin and Inducing Broadly Neutralizing Antibodies
The Journal of Immunology · 2023
- Development of an intracellular quantitative assay to measure compound binding kinetics
Cell chemical biology · 2023
- Evasion of neutralizing antibody responses by the SARS-CoV-2 BA.2.75 variant
Cell Host & Microbe · 2022
- Neutralizing antibody responses against SARS-CoV-2 in vaccinated people with multiple sclerosis
Multiple Sclerosis Journal - Experimental Translational and Clinical · 2022
- A kinetic intra-cellular assay (KICA) to measure quantitative compound binding kinetics within living cells
STAR Protocols · 2022
- Evasion of Neutralizing Antibody Response by the SARS-CoV-2 BA.2.75 Variant
bioRxiv (Cold Spring Harbor Laboratory) · 2022
- Determinants and Mechanisms of the Low Fusogenicity and Endosomal Entry of Omicron Subvariants
bioRxiv (Cold Spring Harbor Laboratory) · 2022
- Evasion of Neutralizing Antibody Response by the SARS-CoC-2 BA.2.75 Variant
SSRN Electronic Journal · 2022
- Neutralizing Antibody Response to SARS-CoV-2 Vaccination in Multiple Sclerosis (P11-4.003)
Neurology · 2022
- Discovery and Characterisation of Highly Cooperative FAK‐Degrading PROTACs
Angewandte Chemie International Edition · 2021
- Role of host factors in SARS-CoV-2 entry
Journal of Biological Chemistry · 2021
- Investigation of Janus Kinase (JAK) Inhibitors for Lung Delivery and the Importance of Aldehyde Oxidase Metabolism
Journal of Medicinal Chemistry · 2021
- bioRxiv (Cold Spring Harbor Laboratory)×10
- medRxiv×5
- Cell Host & Microbe×3
- Proceedings of the National Academy of Sciences×3
- New England Journal of Medicine×3
- Panke Qu
Medicine · The Ohio State University
- Yi-Min Zheng
Medicine · The Ohio State University
- Julia N. Faraone
Medicine · The Ohio State University
- Jingyou Yu
Medicine · The Ohio State University
- Hadi M. Yassine
Medicine · Indiana University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 19, 2026.
Claim or correct this profile